Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers.
Eikenboom EL, van Doorn HC, Dinjens WNM, Dubbink HJ, Geurts-Giele WRR, Spaander MCW, Tops CMJ, Wagner A, Goverde A. Eikenboom EL, et al. Among authors: van doorn hc. Cancers (Basel). 2021 Jan 26;13(3):459. doi: 10.3390/cancers13030459. Cancers (Basel). 2021. PMID: 33530354 Free PMC article.
Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, Hoedemaeker RF, van den Ouweland AM, Hulspas SM, Dubbink HJ, Kuipers EJ, Wagner A, Dinjens WN, Steyerberg EW. Leenen CH, et al. Among authors: van leerdam me, van den ouweland am, van doorn hc, van lier mg. Gynecol Oncol. 2012 May;125(2):414-20. doi: 10.1016/j.ygyno.2012.01.049. Epub 2012 Feb 1. Gynecol Oncol. 2012. PMID: 22306203 Clinical Trial.
Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age.
Goverde A, Spaander MC, van Doorn HC, Dubbink HJ, van den Ouweland AM, Tops CM, Kooi SG, de Waard J, Hoedemaeker RF, Bruno MJ, Hofstra RM, de Bekker-Grob EW, Dinjens WN, Steyerberg EW, Wagner A; LIMO study group. Goverde A, et al. Among authors: van den ouweland am, van doorn hc. Gynecol Oncol. 2016 Dec;143(3):453-459. doi: 10.1016/j.ygyno.2016.10.008. Epub 2016 Oct 24. Gynecol Oncol. 2016. PMID: 27789085
Characteristics of Lynch syndrome associated ovarian cancer.
Woolderink JM, De Bock GH, de Hullu JA, Hollema H, Zweemer RP, Slangen BFM, Gaarenstroom KN, van Beurden M, van Doorn HC, Sijmons RH, Vasen HFA, Mourits MJE. Woolderink JM, et al. Among authors: van doorn hc, van beurden m. Gynecol Oncol. 2018 Aug;150(2):324-330. doi: 10.1016/j.ygyno.2018.03.060. Epub 2018 Jun 5. Gynecol Oncol. 2018. PMID: 29880284
TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer.
Vitale SR, Groenendijk FH, van Marion R, Beaufort CM, Helmijr JC, Dubbink HJ, Dinjens WNM, Ewing-Graham PC, Smolders R, van Doorn HC, Boere IA, Berns EMJJ, Helleman J, Jansen MPHM. Vitale SR, et al. Among authors: van doorn hc, van marion r. Biomolecules. 2020 Mar 7;10(3):415. doi: 10.3390/biom10030415. Biomolecules. 2020. PMID: 32156073 Free PMC article. Clinical Trial.
Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer.
Tjalsma AS, Wagner A, Dinjens WNM, Ewing-Graham PC, Alcalá LSM, de Groot MER, Hamoen KE, van Hof AC, Hofhuis W, Hofman LN, Hoogduin KJ, Kaijser J, Makkus ACF, Mol SJJ, Plaisier GM, Schelfhout K, Smedts HPM, Smit RA, Timmers PJ, Vencken PMLH, Visschers B, van der Wurff AAM, van Doorn HC. Tjalsma AS, et al. Among authors: van der wurff aam, van hof ac, van doorn hc. Gynecol Oncol. 2021 Mar;160(3):771-776. doi: 10.1016/j.ygyno.2020.12.028. Epub 2021 Jan 6. Gynecol Oncol. 2021. PMID: 33419609 Free article.
Exploring Differentially Methylated Genes in Vulvar Squamous Cell Carcinoma.
Dasgupta S, Ewing-Graham PC, Swagemakers SMA, van den Bosch TPP, Atmodimedjo PN, Verbiest MMPJ, de Haan M, van Doorn HC, van der Spek PJ, Koljenović S, van Kemenade FJ. Dasgupta S, et al. Among authors: van der spek pj, van den bosch tpp, van doorn hc, van kemenade fj. Cancers (Basel). 2021 Jul 16;13(14):3580. doi: 10.3390/cancers13143580. Cancers (Basel). 2021. PMID: 34298793 Free PMC article.
PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System.
Corbeau A, Nout RA, Mens JWM, Horeweg N, Godart J, Kerkhof EM, Kuipers SC, van Poelgeest MIE, Kroep JR, Boere IA, van Doorn HC, Hoogeman MS, van der Heide UA, Putter H, Welters MJP, van der Burg SH, Creutzberg CL, de Boer SM. Corbeau A, et al. Among authors: van der heide ua, van poelgeest mie, van doorn hc, van der burg sh. Cancers (Basel). 2021 Oct 15;13(20):5179. doi: 10.3390/cancers13205179. Cancers (Basel). 2021. PMID: 34680328 Free PMC article.
Factors Predicting 30-Day Grade IIIa-V Clavien-Dindo Classification Complications and Delayed Chemotherapy Initiation after Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Prospective Cohort Study.
Kengsakul M, Nieuwenhuyzen-de Boer GM, Udomkarnjananun S, Kerr SJ, van Doorn HC, van Beekhuizen HJ. Kengsakul M, et al. Among authors: van beekhuizen hj, van doorn hc. Cancers (Basel). 2022 Aug 29;14(17):4181. doi: 10.3390/cancers14174181. Cancers (Basel). 2022. PMID: 36077721 Free PMC article.
116 results